Analysis of HCV quasispecies dynamic under selective pressure of combined therapy

Imagem de Miniatura
Arquivos
art_PINHO_Analysis_of_HCV_quasispecies_dynamic_under_selective_pressure_2013.PDF (3.3 MB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
JARDIM, Ana C. G.
BITTAR, Cintia
MATOS, Renata P. A.
YAMASAKI, Lilian H. T.
SILVA, Rafael A.
FACHINI, Roberta M.
CARARETO, Claudia M. A.
CARVALHO-MELLO, Isabel M. V. G. de
RAHAL, Paula
Citação
BMC INFECTIOUS DISEASES, v.13, article ID 61, 16p, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: The quasispecies composition of Hepatitis C virus (HCV) could have important implications with regard to viral persistence and response to interferon-based therapy. The complete NS5A was analyzed to evaluate whether the composition of NS5A quasispecies of HCV 1a/1b is related to responsiveness to combined interferon pegylated (PEG-IFN) and ribavirin therapy. Methods: Viral RNA was isolated from serum samples collected before, during and after treatment from virological sustained responder (SVR), non-responder (NR) and the end-of-treatment responder patients (ETR). NS5A region was amplified, cloned and sequenced. Six hundred and ninety full-length NS5A sequences were analyzed. Results: This study provides evidence that lower nucleotide diversity of the NS5A region pre-therapy is associated with viral clearance. Analysis of samples of NRs and the ETRs time points showed that genetic diversity of populations tend to decrease over time. Post-therapy population of ETRs presented higher genetic distance from baseline probably due to the bottleneck phenomenon observed for those patients in the end of treatment. The viral effective population of those patients also showed a strong decrease after therapy. Otherwise, NRs demonstrated a continuous variation or stability of effective populations and genetic diversity over time that did not seem to be related to therapy. Phylogenetic relationships concerning complete NS5A sequences obtained from patients did not demonstrate clustering associated with specific response patterns. However, distinctive clustering of pre/post-therapy sequences was observed. In addition, the evolution of quasispecies over time was subjected to purifying or relaxed purifying selection. Codons 157 (P03), 182 and 440 (P42), 62 and 404 (P44) were found to be under positive selective pressure but it failed to be related to the therapy. Conclusion: These results confirm the hypothesis that a relationship exists between NS5A heterogeneity and response to therapy in patients infected with chronic hepatitis C.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/2281
Referências
  1. Appel N, 2005, J VIROL, V79, P3187, DOI 10.1128/JVI.79.5.3187-3194.2005
  2. Appel N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000035
  3. Bittar C, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-36
  4. Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200
  5. Chevaliez S, 2007, WORLD J GASTROENTERO, V13, P2461
  6. CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
  7. Cuevas JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003058
  8. Domingo E, 2006, CURR TOP MICROBIOL, V299, P51
  9. Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
  10. Duverlie G, 1998, J GEN VIROL, V79, P1373
  11. Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203
  12. ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025
  13. Ewing B, 1998, GENOME RES, V8, P175
  14. Ewing B, 1998, GENOME RES, V8, P186
  15. Fan WM, 2005, J GASTROENTEROL, V40, P43, DOI 10.1007/s00535-004-1446-2
  16. Farci P, 2002, P NATL ACAD SCI USA, V99, P3081, DOI 10.1073/pnas.052712599
  17. Figlerowicz M, 2010, ARCH VIROL, V155, P1977, DOI 10.1007/s00705-010-0789-7
  18. Forns X, 1999, Clin Liver Dis, V3, P693, DOI 10.1016/S1089-3261(05)70234-8
  19. Forns X., 1999, CLIN LIVER DIS, V3, pvii
  20. Forns X, 1999, TRENDS MICROBIOL, V7, P402, DOI 10.1016/S0966-842X(99)01590-5
  21. Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
  22. Gaudy C, 2005, J CLIN MICROBIOL, V43, P750, DOI 10.1128/JCM.43.2.750-754.2005
  23. Gerotto M, 2000, GASTROENTEROLOGY, V119, P1649, DOI 10.1053/gast.2000.20230
  24. Hutin Y, 2004, J CLIN PHARMACOL, V44, P20, DOI 10.1177/0091270003258669
  25. Gordon D, 1998, GENOME RES, V8, P195
  26. Hall T. A., 1999, NUCL ACIDS S SER, V41, P95, DOI 10.1111/J.1469-8137.2009.02874.X
  27. Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0
  28. Jain MK, 2009, J INFECT DIS, V200, P866, DOI 10.1086/605475
  29. Jardim ACG, 2009, INFECT GENET EVOL, V9, P689, DOI 10.1016/j.meegid.2008.11.001
  30. Le Guillou-Guillemette H, 2007, WORLD J GASTROENTERO, V13, P2416
  31. Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
  32. MARTELL M, 1992, J VIROL, V66, P3225
  33. Marucci EA, 2008, GENET MOL RES, V7, P970
  34. McCormack GP, 2002, REV MED VIROL, V12, P221, DOI 10.1002/rmv.355
  35. Moradpour D, 2004, J VIROL, V78, P7400, DOI 10.1128/JVI.78.14.7400-7409.2004
  36. Murphy DG, 2007, J CLIN MICROBIOL, V45, P1102, DOI 10.1128/JCM.02366-06
  37. Nousbaum JB, 2000, J VIROL, V74, P9028, DOI 10.1128/JVI.74.19.9028-9038.2000
  38. Pascu M, 2004, GUT, V53, P1345, DOI 10.1136/gut.2003.031336
  39. Pawlotsky Jean-Michel, 2003, Clin Liver Dis, V7, P45, DOI 10.1016/S1089-3261(02)00065-X
  40. Pawlotsky JM, 2003, ANTIVIR RES, V59, P1, DOI 10.1016/S0166-3542(03)00088-3
  41. Pawlotsky JM, 1998, J VIROL, V72, P2795
  42. Pawlotsky JM, 1999, J VIRAL HEPATITIS, V6, P343, DOI 10.1046/j.1365-2893.1999.00185.x
  43. Pawlotsky JM, 2005, SEMIN LIVER DIS, V25, P72, DOI 10.1055/s-2005-864783
  44. Pawlotsky JM, 1998, J MED VIROL, V54, P256, DOI 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.3.CO;2-K
  45. Pellerin M, 2004, J VIROL, V78, P4617, DOI 10.1128/JVI.78.9.4617-4627.2004
  46. Penin F, 2004, J BIOL CHEM, V279, P40835, DOI 10.1074/jbc.M404761200
  47. Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
  48. Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
  49. Puig-Basagoiti F, 2005, J GEN VIROL, V86, P1067, DOI 10.1099/vir.0.80526-0
  50. Ramirez S, 2010, J GEN VIROL, V91, P1183, DOI 10.1099/vir.0.018929-0
  51. Ray SC, 1999, J VIROL, V73, P2938
  52. SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547
  53. Salmeron J, 2006, DIGEST DIS SCI, V51, P960, DOI 10.1007/s10620-006-9347-2
  54. Saludes V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014132
  55. Satoh S, 2000, VIROLOGY, V270, P476, DOI 10.1006/viro.2000.0287
  56. Sauter D, 2009, J HEPATOL, V50, P861, DOI 10.1016/j.jhep.2008.11.024
  57. Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
  58. Swofford DL, 2003, VERSION 4
  59. Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
  60. Tellinghuisen TL, 2004, J BIOL CHEM, V279, P48576, DOI 10.1074/jbc.M407787200
  61. Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
  62. Toyoda H, 1997, J HEPATOL, V26, P6, DOI 10.1016/S0168-8278(97)80002-5
  63. Ueda E, 2004, HEPATOL RES, V29, P89, DOI 10.1016/j.jhepres.2004.02.014
  64. Witherell GW, 2001, J MED VIROL, V63, P8, DOI 10.1002/1096-9071(200101)63:1<8::AID-JMV1001>3.3.CO;2-B
  65. Xu ZK, 2008, J VIROL, V82, P9417, DOI 10.1128/JVI.00896-08
  66. Yang ZH, 1998, MOL BIOL EVOL, V15, P568
  67. Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555
  68. Yang ZH, 2002, CURR OPIN GENET DEV, V12, P688, DOI 10.1016/S0959-437X(02)00348-9
  69. Zekri ARN, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-16

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03